Cervagem, Softcover reprint of the original 1st ed. 1983 A new prostaglandin in obstetrics and gynaecology Proceedings of a Symposium held at the Shangri-La Hotel, Singapore, 31 July 1982.

Honourable Chairman, distinguished speakers, ladies and gentlemen, May & Baker, Singapore is proud to play a part in organizing and hosting this symposium. I hope that it is not necessary for me to intro­ duce myself, as Singapore doctors have received my letter of invitation and overseas delegates have received my letter of welcome. It is my very pleasant duty to introduce our Director of Research, Dr J. A. McFadzean, who has come specially to grace this occasion. Dr McFadzean, Sir, may I invite you to say a few words to this gathering of distinguished participants. TanJoo Hock VUl Welcome It is my privilege on behalf of May & Baker to welcome you here today. We have representatives from nine countries - Singapore, Malaysia, Thailand, Hong Kong, Indonesia, Japan, Norway, Sweden and UK. It is appropriate that this Symposium on Cervagem be held in South-east Asia where so much excellent development work was done with this product. Cervagem has resulted from many years of collaborative research and development between May & Baker and the Ono Pharmaceutical Company of Japan. It has been a most happy collaboration from the time the active ingredient ONO-802 was synthesized by the Ono Company. You will hear today of the stage we have reached with the R&D work.

1 Comparison of the pharmacological and biochemical properties of ONO-802 (Cervagem) and the naturally occurring prostaglandins.- 2 Clinical applications of prostaglandins in obstetrics and gynaecology.- Discussion 1.- 3 Preoperative cervical dilation: comparative study of Cervagem and Sulprostone in first trimester abortion.- 4 Pre-evacuation cervical dilatation in termination of pregnancy.- 5 Cervagem clinical trials review. Part 1: preoperative cervical dilatation in pregnant women.- Discussion 2.- 6 Clinical experience with selected prostaglandin analogues in obstetrics and gynaecology.- 7 Clinical study of Cervagem (ONO-802) for application in first and second trimester abortions in Japan.- Discussion 3.- 8 Cervagem clinical trials review. Part 2: second trimester therapeutic termination of pregnancy, and other applications.- Introduction: Cervagem future development.- 9 Cervagem future development: proposed clinical evaluation by the prescriber.- Discussion 4 and future developments.- Chairman’s concluding remarks.- 10 Preoperative cervical dilatation by vaginal pessaries containing a prostaglandin E1, analogue (gemeprost, Cervagem) (Invited paper, not presented at the symposium).